Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Phase 2 Unknown 78 enrolled AB Science

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.

Timeline

Start: 2021-11-23
Primary completion: 2023-12
Completion: 2023-12

Publications

Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chem Res Toxicol. 2022 Sep 19;35(9):1467-1481. doi: 10.1021/acs.chemrestox.2c00057. Epub 2022 Sep 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Masitinib	Small molecule	3 mg/kg	—
Subject	Masitinib	Small molecule	4.5 mg/kg	—
Subject	Masitinib	Small molecule	6 mg/kg	—

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Summary

Timeline

Publications

Drugs

Indications